Target intelligence / Profile preview

Staphylococcus aureus 50S ribosomal subunit (50S subunit)

Target
50S subunit
Molecular classification
Enzyme, Other
01

Overview

The Staphylococcus aureus 50S ribosomal subunit is a massive ribonucleoprotein complex that serves as the catalytic heart of the bacterial translation machinery (Wilson, 2014, Nature Reviews Microbiology) [1]. It is composed of the 23S and 5S ribosomal RNAs (rRNA) and approximately 34 ribosomal proteins, which together coordinate the formation of peptide bonds at the peptidyl transferase center (PTC) and the subsequent passage of the nascent protein through the exit tunnel (Belousoff et al., 2017, Molecular Cell) [2]. Because protein synthesis is essential for bacterial viability and the production of virulence factors, this subunit is a premier target for several classes of antibiotics used to treat Staphylococcus aureus infections, including those caused by methicillin-resistant (MRSA) strains (StatPearls, 2023) [3]. Drugs such as macrolides, lincosamides, and oxazolidinones bind to specific pockets within the 23S rRNA, effectively halting translation by either preventing peptide bond formation or physically obstructing the exit tunnel (Eyal et al., 2015, PNAS) [4]. However, the clinical utility of these drugs is frequently challenged by the evolution of resistance mechanisms, such as the enzymatic methylation of the 23S rRNA by Erm or Cfr methyltransferases, which prevents drug binding (Munita & Arias, 2016, Microbiology Spectrum) [5].

Other names
Staphylococcus aureus large ribosomal subunit50S ribosomeLarge ribosomal subunit23S/5S ribosomal complex
02

Mechanism of action

Inhibition of bacterial protein synthesis by binding to the 23S rRNA of the 50S ribosomal subunit, which interferes with peptidyl transferase activity or blocks the nascent peptide exit tunnel.

03

Biological functions

Other
04

Disease associations

Infection
05

Safety considerations

Antimicrobial resistance (e.g., MRSA, VRSA)Disruption of the commensal microbiomeMitochondrial toxicity (e.g., myelosuppression or peripheral neuropathy with oxazolidinones)Gastrointestinal distress
06

Interacting drugs

Linezolid

10 more in the full profile.

07

Biomarkers

23S rRNA mutationsermA/B/C gene presencecfr gene presenceAntibiotic susceptibility (MIC)

Beyond the preview

Go deeper on Staphylococcus aureus 50S ribosomal subunit (50S subunit).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Staphylococcus aureus 50S ribosomal subunit (50S subunit).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call